AaviGen raises 17 million € in second financing round to advance precision gene therapies for heart failure towards the clinical stage
AaviGen GmbH, a preclinical stage biotechnology company focused on the development of curative gene therapies for cardiovascular and cardiopulmonary diseases, announced the completion of its 17M € Series B financing round. Building on AaviGen’s proprietary portfolio of engineered cardiac-specific adeno-associated viral (AAV) capsids, the funding will enable the expansion of its preclinical programs and accelerate its lead gene therapy medicinal product (GTMP) for chronic heart failure towards the clinic. DH-LT investments GmbH, an investment company led by Dietmar Hopp, commits the financing for the Series B to expand its existing shareholding in AaviGen.
Although current AAV-based gene therapy approaches have shown efficacy in several rare diseases, previous gene medicine developments directed against heart failure were hindered by imprecise targeting and the inability to transduce the heart effectively. AaviGen’s advanced AAV engineering platform is designed to develop differentiated AAV capsids optimized to target the diseased cardiovascular and cardiopulmonary system and to limit transduction of tissues and cell types that are not relevant to the target disease. In executing its lead GTMP program, AaviGen builds on the expertise and track record of its founders and leadership team as well as the experience and commitment of its investor: “Despite the steadily growing prevalence of heart failure, which affects more than 26 million people worldwide, there are essentially no curative therapies available targeting the underlying molecular causes. AaviGen’s therapeutic pipeline aspires to address this critical unmet need. Our highly innovative cardiac-targeted vector generation delivers therapeutic genes against the molecular and genetic foundation of acquired and hereditary heart failure with unprecedented safety and efficacy via a single intravenous injection”, commented Prof. Patrick Most, co-founder, CEO and Managing Director of AaviGen. “We are convinced that AaviGen’s innovative approach to delivering gene medicines to diseased tissues can become a game changer for the gene therapy field. Therefore, we are excited to continue supporting AaviGen in developing its therapeutic candidate for heart failure towards the clinic”, said Dietmar Hopp.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
